Literature DB >> 31361567

The use of off-label medications in substance abuse treatment programs.

Maria Paino1, Lydia Aletraris2, Paul M Roman2.   

Abstract

Background: Substance use disorder (SUD) treatment centers serve a population of clients who have diverse needs, and may desire or require access to varied treatments while seeking care for their SUDs. While pharmacotherapies have increased in popularity for the treatment of SUDs, adoption rates do remain quite low. But a wider array of pharmacotherapies has become available in recent years which may shift the trend. This article helps shed light on how variations in SUD treatment centers develop and persist with regard to the adoption and delivery of off-label medications.
Methods: We use a nationally representative and longitudinal sample of SUD treatment centers in the US (N = 196). We use a logistic regression to analyze the relationship between organizational characteristics and offering any medications, off-label. We also use a negative binomial regression to analyze the relationship between organizational characteristics and the number of medications that were used off-label.
Results: Our findings reveal that older centers, accredited centers, and centers that offer mental health screenings are all positively associated with the provision of off-label medication in SUD treatment. We also find a positive relationship between private funding and offering a greater number of off-label medications. Conclusions: Our results suggest that SUD clients who seek treatment from centers that offer medications off-label, may have access to a greater number of medication-assisted treatment options.

Entities:  

Keywords:  Medication-assisted treatment; Off-label medication; substance use disorders; treatment centers

Year:  2019        PMID: 31361567      PMCID: PMC6989348          DOI: 10.1080/08897077.2019.1635962

Source DB:  PubMed          Journal:  Subst Abus        ISSN: 0889-7077            Impact factor:   3.716


  35 in total

1.  Regulating off-label drug use--rethinking the role of the FDA.

Authors:  Randall S Stafford
Journal:  N Engl J Med       Date:  2008-04-03       Impact factor: 91.245

2.  Dissemination, adoption, and implementation of acamprosate for treating alcohol use disorders.

Authors:  Hannah K Knudsen; Paul M Roman
Journal:  J Stud Alcohol Drugs       Date:  2014-05       Impact factor: 2.582

3.  A pilot, open clinical study of depakote in the treatment of cocaine abuse.

Authors:  James A. Halikas; Bruce A. Center; Victoria L. Pearson; Gregory A. Carlson; Fredrick Crea
Journal:  Hum Psychopharmacol       Date:  2001-04       Impact factor: 1.672

4.  Divalproex loading in the treatment of cocaine dependence.

Authors:  H Myrick; S Henderson; K T Brady; R Malcom; M Measom
Journal:  J Psychoactive Drugs       Date:  2001 Jul-Sep

Review 5.  Topiramate in the treatment of cocaine use disorder.

Authors:  Valerie Prince; Kellie C Bowling
Journal:  Am J Health Syst Pharm       Date:  2018-01-01       Impact factor: 2.637

Review 6.  Pharmacotherapy of dual substance abuse and dependence.

Authors:  George A Kenna; Darci M Nielsen; Patricia Mello; Alison Schiesl; Robert M Swift
Journal:  CNS Drugs       Date:  2007       Impact factor: 5.749

7.  Topiramate's effects on cocaine-induced subjective mood, craving and preference for money over drug taking.

Authors:  Bankole A Johnson; John D Roache; Nassima Ait-Daoud; Erik W Gunderson; Heather M Haughey; Xin-Qun Wang; Lei Liu
Journal:  Addict Biol       Date:  2012-10-08       Impact factor: 4.280

Review 8.  Efficacy and tolerability of baclofen in substance use disorders: a systematic review.

Authors:  Roberta Agabio; Antonio Preti; Gian Luigi Gessa
Journal:  Eur Addict Res       Date:  2013-06-15       Impact factor: 3.015

Review 9.  Is baclofen a revolutionary medication in alcohol addiction management? Review and recent updates.

Authors:  Mohamed-Ali Gorsane; Oussama Kebir; Guillaume Hache; Lisa Blecha; Henri-Jean Aubin; Michel Reynaud; Amine Benyamina
Journal:  Subst Abus       Date:  2012       Impact factor: 3.716

10.  Baclofen for the Treatment of Alcohol Dependence and Possible Role of Comorbid Anxiety.

Authors:  K C Morley; A Baillie; S Leung; G Addolorato; L Leggio; P S Haber
Journal:  Alcohol Alcohol       Date:  2014-09-21       Impact factor: 2.826

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.